The Medical Letter on Drugs and Therapeutics
Futibatinib (Lytgobi) for Cholangiocarcinoma (online only)
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Futibatinib (Lytgobi) for Cholangiocarcinoma (online only)
The oral kinase inhibitor futibatinib (Lytgobi – Taiho) has received accelerated approval from the FDA for treatment of adults with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma with...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Futibatinib (Lytgobi) for Cholangiocarcinoma (online only)
Article code: 1674f
 Electronic, downloadable article - $45

Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.